Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 13
2020 15
2021 21
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

44 results
Results by year
Filters applied: . Clear all
Page 1
Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
Papi A, Virchow JC, Singh D, Kots M, Vele A, Georges G, Canonica GW. Papi A, et al. J Allergy Clin Immunol. 2021 Jul;148(1):262-265.e2. doi: 10.1016/j.jaci.2021.01.007. Epub 2021 Jan 21. J Allergy Clin Immunol. 2021. PMID: 33485959 Free article.
A single-inhaler triple therapy containing extrafine formulations of the inhaled corticosteroid (ICS) beclomethasone dipropionate (BDP), long-acting beta(2)-agonist formoterol fumarate (FF), and long-acting muscarinic antagonist glycopyrronium (G) is i …
A single-inhaler triple therapy containing extrafine formulations of the inhaled corticosteroid (ICS) beclomethasone dipropionate
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting beta(2)-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E. Ferguson GT, et al. Adv Ther. 2020 Jun;37(6):2956-2975. doi: 10.1007/s12325-020-01311-3. Epub 2020 Apr 25. Adv Ther. 2020. PMID: 32335859 Free PMC article.
INTRODUCTION: Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta(2)-agonist (ICS/LAMA/LABA) combination therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who experience further exacerbations/symptoms on dual LAMA/L …
INTRODUCTION: Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta(2)-agonist (ICS/LAMA/LABA) combination therap …
Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
Pohunek P, Varoli G, Reznichenko Y, Mokia-Serbina S, Brzostek J, Kostromina V, Kaladze M, Muraro A, Carzana E, Armani S, Kaczmarek J. Pohunek P, et al. Eur J Pediatr. 2021 May;180(5):1467-1475. doi: 10.1007/s00431-020-03888-x. Epub 2021 Jan 6. Eur J Pediatr. 2021. PMID: 33404895 Clinical Trial.
A new pediatric fixed combination of beclometasone dipropionate (BDP) 50 mug and formoterol fumarate (FF) 6 mug via pressurized metered-dose inhaler (pMDI) (CHF1535, Chiesi, Italy) was investigated. ...What is New: A novel pediatric pMDI fixed combinat …
A new pediatric fixed combination of beclometasone dipropionate (BDP) 50 mug and formoterol fumarate (FF) 6 mug …
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Virchow JC, et al. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. Lancet. 2019. PMID: 31582314 Clinical Trial.
Here we report on two studies that compared the single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting beta(2) agonist), and glycopyrronium (G; long-acting muscarinic antag …
Here we report on two studies that compared the single-inhaler extrafine combination of beclometasone dipropionate (BDP; inhal …
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
Kupczyk M, Kuna P. Kupczyk M, et al. Expert Rev Respir Med. 2019 Jan;13(1):5-11. doi: 10.1080/17476348.2019.1548937. Epub 2018 Nov 27. Expert Rev Respir Med. 2019. PMID: 30463457 Review.
Areas covered: The first triple fixed-dose combination of extrafine beclomethasone/formoterol/glycopyrronium in one pMDI type inhaler intended for the treatment of COPD has been registered in Europe in 2017. ...
Areas covered: The first triple fixed-dose combination of extrafine beclomethasone/formoterol/glycopyrronium in one pMDI type …
Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
Voorham J, Baldi S, Santoro L, Kerkhof M, Contoli M, Fabbri LM, Kerstjens HAM, Luis López-Campos J, Roche N, Singh D, Vogelmeier CF, Price DB. Voorham J, et al. Int J Chron Obstruct Pulmon Dis. 2020 Oct 29;15:2739-2750. doi: 10.2147/COPD.S269287. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33149571 Free PMC article.
PURPOSE: This study aimed to evaluate the non-inferiority of initiating extrafine beclometasone dipropionate/formoterol fumarate (BDP/FF) versus double bronchodilation (long-acting beta-agonists [LABA]/long-acting muscarinic antagonists [LAMA]) among p …
PURPOSE: This study aimed to evaluate the non-inferiority of initiating extrafine beclometasone dipropionate/formoterol
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Rogliani P, et al. Br J Pharmacol. 2020 Mar;177(5):1150-1163. doi: 10.1111/bph.14909. Epub 2020 Jan 29. Br J Pharmacol. 2020. PMID: 31660611 Free PMC article.
This study characterized the interaction between the ICS beclomethasone dipropionate, the LABA formoterol fumarate and the LAMA glycopyrronium bromide in human airways. ...The interaction was assessed by using Bliss Independence and Unified Theory theo …
This study characterized the interaction between the ICS beclomethasone dipropionate, the LABA formoterol fumarate
An innovative corticosteroid/long-acting beta(2)-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma.
Usmani O, Roche N, Marshall J, Danagher H, Price D. Usmani O, et al. Expert Opin Drug Deliv. 2019 Dec;16(12):1367-1380. doi: 10.1080/17425247.2019.1689957. Epub 2019 Nov 28. Expert Opin Drug Deliv. 2019. PMID: 31752560 Review.
Until recently, no inhaled corticosteroid/long-acting beta(2)-agonist combination BTI was available in Europe. The flutiform (fluticasone propionate/formoterol fumarate [FP/FORM]) k-haler is the first combination BTI now approved in Europe for asthma maintenance tre …
Until recently, no inhaled corticosteroid/long-acting beta(2)-agonist combination BTI was available in Europe. The flutiform (fluticasone pr …
Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P, Patrucco F, Bagnasco D. Solidoro P, et al. Expert Rev Respir Med. 2019 Nov;13(11):1087-1094. doi: 10.1080/17476348.2019.1665514. Epub 2019 Sep 13. Expert Rev Respir Med. 2019. PMID: 31498714 Review.
At least four fixed-dose ICS/LABA combinations are available, including budesonide/formoterol, beclomethasone/formoterol, fluticasone/vilanterol and fluticasone/salmeterol, but there is little guidance for clinicians on which of these combinations to prescrib …
At least four fixed-dose ICS/LABA combinations are available, including budesonide/formoterol, beclomethasone/formoterol
Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G. Beeh KM, et al. Int J Chron Obstruct Pulmon Dis. 2021 Jan 14;16:79-89. doi: 10.2147/COPD.S291030. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 33488071 Free PMC article. Clinical Trial.
BACKGROUND: Three 52-week studies in COPD have assessed the efficacy and safety of single-inhaler extrafine formulation triple therapy combining beclomethasone dipropionate (BDP), formoterol fumarate (FF) and glycopyrronium (G) delivered via pressurize …
BACKGROUND: Three 52-week studies in COPD have assessed the efficacy and safety of single-inhaler extrafine formulation triple therapy combi …
44 results